By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Akonni Biosystems has raised about $935,000 of a targeted $20 million offering, the molecular diagnostics firm disclosed in a document filed with the US Securities and Exchange Commission.

The raise is in the form of equity, it said. The company said three investors participated in the round but did not identify them. It also did not provide an intended use of the proceeds and did not respond to a request for comment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.